



## Complete Summary

---

### GUIDELINE TITLE

Acne.

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Acne. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2003 Jun 15 [Various]. [12 references]

## COMPLETE SUMMARY CONTENT

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

CONTRAINDICATIONS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY

## SCOPE

### DISEASE/CONDITION(S)

Acne, including:

- Comedonic acne (A. comedonicus)
- Common acne (A. vulgaris) or pustular acne
- Cystic acne (A. cystica)
- Acne conglobata
- Acne fulminans

### GUIDELINE CATEGORY

Treatment

### CLINICAL SPECIALTY

Dermatology  
Family Practice  
Internal Medicine

## INTENDED USERS

Health Care Providers  
Physicians

## GUIDELINE OBJECTIVE(S)

Evidence-Based Medicine Guidelines collects, summarizes, and updates the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.

## TARGET POPULATION

Patients with acne

## INTERVENTIONS AND PRACTICES CONSIDERED

### Treatment

1. Skin cleansing with soap or antibacterial detergents
2. Treatment of comedonic acne with retinoic acid cream or solution, adapalen gel, or benzoyl peroxide (3-10%)
3. Treatment of common acne with local antibiotics (e.g. clindamycin ointment), selective ultraviolet phototherapy (SUP), and systemic treatment as indicated
4. Systemic antibiotics (tetracycline, erythromycin)
5. Local treatment and light therapy in conjunction with systemic treatment
6. Incision and drainage of pus-containing cysts with a large-caliber injection needle or narrow-tipped scalpel
7. Hormonal treatment for women: Cyproterone acetate (an anti-androgen) + oestrogen
8. Treatment of scars by skin abrasion or laser therapy (by a dermatologist or a plastic surgeon)
9. Isotretinoin upon recommendation of a dermatologist
10. Consultation with or referral to a dermatologist

Note: Guideline developers considered spironolactone as treatment of hirsutism and acne; however, there was not enough data to evaluate the effectiveness.

## MAJOR OUTCOMES CONSIDERED

- Efficacy of treatment
- Adverse effects of treatment

## METHODOLOGY

### METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

## DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.

## NUMBER OF SOURCE DOCUMENTS

Not stated

## METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

## RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of Evidence

A: Strong research-based evidence. Several relevant, high-quality scientific studies with homogeneous results.

B: Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.

C: Limited research-based evidence. At least one adequate scientific study.

D: No scientific evidence. Expert panel evaluation of other information.

## METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

## DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

## RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

## COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

## METHOD OF GUIDELINE VALIDATION

Peer Review

## DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

#### Classification of Acne

- Comedonic acne (A. comedonicus)
  - Plenty of open or obstructed comedos, but scant inflammatory changes
- Common acne (A. vulgaris) or pustular acne
  - Pustules and comedos
- Cystic acne (A. cystica)
  - Cystic foci of infection that result in scars
- Acne conglobata
  - Multilobular inflammatory cysts containing volatile pus
  - Therapy-resistant, scar-forming
- Acne fulminans
  - An uncommon variant of acne in young men characterized by systemic symptoms (fever, arthralgia, skeletal foci of inflammation)
  - Systemic corticosteroids, not antibiotics, are the drugs of choice.
  - Refer patients with suspected acne fulminans to a dermatologist without delay. The painful disease is not well-known, and is often left untreated for a long time.

#### Treatment

##### Local Treatment

- Local treatment is usually sufficient for comedonic acne and mild common acne.
- Wash the skin with soap or antibacterial detergents.
- Comedonic acne can be treated with
  - Retinoic acid cream or solution
  - Adapalene gel
  - Benzoyl peroxide (3-10%)
  - All above drugs can be irritating at first. Use a low concentration of the active drug initially, and advise the patient to wash the drug away after a few hours. The tolerance of the skin increases with time.
- Common acne can be treated with
  - Local antibiotics (e.g. clindamycin ointment)

- Selective ultraviolet phototherapy (SUP) (as a course of 15 treatments added to other treatment) for widespread disease
- Consider systemic treatment if local treatment is unsuccessful 2 to 3 months from the onset of treatment.

### Systemic Treatment

- Antibiotics
  - Tetracycline (Garner et al., 2002) [B] or erythromycin are equally effective. The usual dose is 250 to 500 mg/day for a few months. Six months' treatment with tetracycline or erythromycin 1 g/day is more effective than a shorter treatment with a smaller dose. Do not use tetracyclines in children under 12 years of age.
  - Local treatment and light therapy can be used simultaneously with systemic treatment.
  - Local treatment is not sufficient in cystic acne and conglobate acne. Use systemic antibiotics or consider referral to a dermatologist. Pus-containing cysts can be drained by incising them with a large-caliber injection needle or narrow-tipped scalpel.
- Hormonal treatment for women
  - Cyproterone acetate (an anti-androgen) + oestrogen for 6 months reduces the excretion of sebaceous glands and alleviates acne.

### Acne Scars

- Consider treatment of scars by skin abrasion or laser therapy (Jordan, Cummins, & Burls, West Midlands, 1998; Jordan, Cummins, & Burls, Birmingham, 1998; DARE-999269, 2001; HTA-998502, 2001) [D] only after the activity of the disease has totally subsided.
- Scars can be treated either by a dermatologist or a plastic surgeon.

### Indications for Specialist Consultation

- Severe forms of acne (A. cystica, conglobata, fulminans)
- If ordinary treatment fails, the dermatologist can consider isotretinoin. However, it has considerable teratogenicity.

### Related Evidence

- There is not enough data to evaluate the effectiveness of spironolactone as treatment of hirsutism and acne (Lee et al., 2002) [D].

### Definitions:

#### Levels of Evidence

A: Strong research-based evidence. Several relevant, high-quality scientific studies with homogeneous results.

B: Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.

C: Limited research-based evidence. At least one adequate scientific study.

D: No scientific evidence. Expert panel evaluation of other information.

#### CLINICAL ALGORITHM(S)

None provided

### EVIDENCE SUPPORTING THE RECOMMENDATIONS

#### REFERENCES SUPPORTING THE RECOMMENDATIONS

[References open in a new window](#)

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

### BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### POTENTIAL BENEFITS

Effective treatment of acne

#### POTENTIAL HARMS

Adverse Effects of Medication

- Retinoic acid cream or solution, adapalene gel, and benzoyl peroxide (3-10%) can be irritating at first. The tolerance of the skin increases with time.
- Isotretinoin has considerable teratogenicity.

### CONTRAINDICATIONS

#### CONTRAINDICATIONS

Warning: Tetracyclines should not be used in children under 12 years of age.

### IMPLEMENTATION OF THE GUIDELINE

#### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Acne. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2003 Jun 15 [Various]. [12 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2001 Apr 30 (revised 2003 Jun 15)

### GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

### SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

### GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Jorma Lauharanta

### FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Acne. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2001 Apr 30. Various p.

#### GUIDELINE AVAILABILITY

This guideline is included in a CD-ROM titled "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: [info@ebm-guidelines.com](mailto:info@ebm-guidelines.com); Web site: [www.ebm-guidelines.com](http://www.ebm-guidelines.com).

#### AVAILABILITY OF COMPANION DOCUMENTS

None available

#### PATIENT RESOURCES

None available

#### NGC STATUS

This summary was completed by ECRI on December 17, 2002. The information was verified by the guideline developer as of February 7, 2003. This summary was updated by ECRI on March 29, 2004.

#### COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

© 1998-2004 National Guideline Clearinghouse

Date Modified: 11/15/2004

**FIRSTGOV**





